# Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

> **NCT07303881** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 16 (estimated)

## Conditions studied

- IrAE
- Hematologic Disorder
- Lung Cancer (Locally Advanced or Metastatic)

## Interventions

- **DRUG:** golidocitinib

## Key facts

- **NCT ID:** NCT07303881
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303881, "Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07303881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*